Avastin® is the official global commercial brand name, and Anweiting is its Chinese brand name developed by Roche. It is a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF). It blocks VEGF-mediated tumor angiogenesis, cutting off the blood supply of malignant lesions to inhibit tumor growth and metastasis
Main Indications
Combination therapy for metastatic colorectal cancer in adult patients;
First-line combined treatment of unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer;
Combined chemotherapy for epithelial ovarian, fallopian tube or primary peritoneal cancer;
Combined therapy for recurrent or metastatic cervical cancer;
Monotherapy or combined treatment for recurrent glioblastoma in adults.
Clinical Research
Global multicenter phase III pivotal trials fully validated its progression-free survival benefit when added to standard chemotherapy for multiple solid tumor types;
Head-to-head controlled registration trials confirmed significant reduction in tumor angiogenesis and distant metastasis risk versus chemotherapy alone;
Long-term follow-up cohort studies demonstrated sustained disease stabilization under regular intravenous maintenance cycles;
Dose-finding research verified balanced anti-tumor efficacy and bleeding/hypertension safety profile of the 100mg (4mL) specification;
Chinese domestic registration trials confirmed consistent therapeutic activity and manageable adverse reaction spectrum for domestic patients with lung, colorectal and gynecological malignancies.
Common Side Effects
Common mild adverse reactions: Hypertension, proteinuria, fatigue, diarrhea, epistaxis and headache;
Laboratory abnormalities: Transient urine protein elevation, mild thrombocytopenia and hypoalbuminemia;
Severe but uncommon risks: Gastrointestinal perforation, severe hemorrhage, arterial thromboembolism, reversible posterior leukoencephalopathy syndrome and wound healing complications.
Approval Status in China
Original drug Avastin® (Chinese brand: Anweiting) was officially approved for marketing in China in 2010, with the specification of 100mg (4mL) per vial, 1 vial per box. It is currently a prescription anti-angiogenic targeted drug included in China’s Category B medical insurance catalogue.
Buy Avastin (Bevacizumab Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
